Certain medications which influence insulin resistance, including metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists, have modest cardiovascular benefits although the exact mechanism is not known (18, 19). This evidence concerns the gene GLP1R and Insulin resistance.